每经AI快讯，10月17日，创新药概念股延续活跃，华邦健康涨停，申联生物、舒泰神、辰欣药业、维 康药业、海特生物跟涨。 （文章来源：每日经济新闻） ...

维康药业公开发行募集资金总额为83,134.74万元，扣除发行费用后，募集资金净额为72,559.56万 元。维康药业最终募集资金净额较原计划多18,554.56万元。维康药业于2020年8月19日披露的招股书显 示，公司拟募集资金54,005.00万元，分别用于医药大健康产业园一期项目（中药饮片及中药提取、研发 中心、仓储中心）、营销网络中心建设项目、补充营运资金项目。 | | 2024 年 | 2023 年 | | 本年比上年增 減 | 2022年 | | | --- | --- | --- | --- | --- | --- | --- | | | | 调整前 | 调整后 | 调整后 | 调整前 | 调整后 | | 营业收入 | 351.198.567.67 | 519,621,071.15 | 519.621.071.15 | -32.41% | 532.441.947.54 | 532.441.947.54 | | (元) | | | | | | | | 归属于上市公 司股东的净利 | -147.426.253.43 | -8,038,557.83 | -8.954.344.50 | -1.546. ...

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

Market Overview - On September 26, the Traditional Chinese Medicine (TCM) sector declined by 0.38%, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3828.11, down 0.65%, while the Shenzhen Component Index closed at 13209.0, down 1.76% [1] Stock Performance - Notable gainers in the TCM sector included: - *ST Changyao: Closed at 3.88, up 3.47% with a trading volume of 134,100 shares [1] - Fangsheng Pharmaceutical: Closed at 12.08, up 2.11% with a trading volume of 274,600 shares [1] - Huaren Sanjiu: Closed at 28.39, up 1.50% with a trading volume of 133,600 shares [1] - Major decliners included: - Weikang Pharmaceutical: Closed at 23.66, down 6.30% with a trading volume of 81,000 shares [2] - Zhendong Pharmaceutical: Closed at 6.57, down 4.09% with a trading volume of 518,000 shares [2] - Zhongsheng Pharmaceutical: Closed at 17.00, down 2.41% with a trading volume of 295,000 shares [2] Capital Flow - The TCM sector experienced a net outflow of 298 million yuan from institutional investors, while retail investors saw a net inflow of 396 million yuan [2] - Key stocks with significant capital flow included: - Huaren Sanjiu: Net inflow of 44.98 million yuan from institutional investors [3] - Fangsheng Pharmaceutical: Net inflow of 33.39 million yuan from institutional investors [3] - Dong'e Ejiao: Net inflow of 32.19 million yuan from institutional investors [3]

Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]

本报讯(记者吴文婧)9月25日晚，浙江维康药业（300878）股份有限公司(以下简称"维康药业")发布公 告，当日，由维康药业与盈科瑞(珠海金湾)制药有限公司共同申办、上海中医药大学附属曙光医院牵头 的"黄甲软肝颗粒"Ⅲ期临床试验项目启动会召开。该试验旨在评价该药物治疗慢性乙型肝炎肝纤维化的 有效性和安全性，共有包括安徽医科大学第一附属医院等19家中心参与。 维康药业多年来深耕中医药领域，目前已发展成为一家现代化高科技制药企业。此次启动临床三期试验 的"黄甲软肝颗粒"，适应症为"慢性乙型病毒性肝炎肝纤维化(肝郁脾虚兼瘀血阻络证)"，属于乙肝的一 种疾病后期。此次临床试验将采用随机、双盲、安慰剂对照、多中心设计，计划纳入480例受试者，旨 在最终验证其安全性与有效性。已完成的Ⅱ期临床试验结果显示，"黄甲软肝颗粒"在治疗相关适应症方 面，具有良好的疗效和安全性，患者临床获益超过潜在风险。 相关资料显示，我国慢乙肝患者基数庞大，2030年消灭乙肝目标明确。根据2023年《中华肝脏病杂 志》，我国慢性乙肝诊断率和治疗率分别仅为22%和15%，仍然有较大的提升空间。 国家药品监督管理局药品审批中心(CDE)药物临床试验 ...

证券日报网讯 9月25日晚间，维康药业发布公告称，2025年9月25日，公司与盈科瑞（珠海金湾）制药 有限公司共同申办，牵头单位为上海中医药大学附属曙光医院和参研的安徽医科大学第一附属医院、重 庆大学附属三峡医院、重庆医科大学附属第一医院等19家临床试验中心组织召开了关于开展"评价黄甲 软肝颗粒治疗慢性乙型病毒性肝炎肝纤维化（肝郁脾虚兼瘀血阻络证）的有效性和安全性的随机、双 盲、多中心、安慰剂对照的Ⅲ期临床试验"的项目启动会。 （编辑 任世碧） ...

Group 1 - The core point of the news is the initiation of a Phase III clinical trial for Huangjia Suohan Granules, aimed at evaluating its efficacy and safety in treating chronic hepatitis B-related liver fibrosis [1][2] - The Phase III trial will include 480 participants and is designed as a randomized, double-blind, placebo-controlled, multi-center study [1] - The results from the completed Phase II trial indicated that Huangjia Suohan Granules have good clinical efficacy and safety, with patient benefits outweighing potential risks [1] Group 2 - There are four other traditional Chinese medicines undergoing clinical trials for liver fibrosis, indicating a competitive landscape in this therapeutic area [2] - Weikang Pharmaceutical, headquartered in Lishui, Zhejiang, focuses on the research, production, and sales of modern Chinese and Western medicines, with a strong emphasis on antibiotic and gynecological drug development [2] - The company's main products include Yinhuang Diban, Yimucao Soft Capsules, and other traditional Chinese medicines, as well as Western medicines like Roxithromycin Soft Capsules [2] Group 3 - Following the announcement of the Phase III trial, Weikang Pharmaceutical's stock price surged, with an increase of over 13% at one point, closing with a gain of 9.83% [3]

Core Viewpoint - The announcement of the initiation of the Phase III clinical trial for "Huangjia Soft Liver Granules" by Weikang Pharmaceutical and its partners marks a significant step in evaluating the drug's efficacy and safety for treating chronic hepatitis B liver fibrosis [1][2]. Group 1: Clinical Trial Details - The Phase III clinical trial aims to assess the effectiveness and safety of "Huangjia Soft Liver Granules" for chronic hepatitis B liver fibrosis, involving 19 centers including Anhui Medical University First Affiliated Hospital [1][2]. - The trial will include 480 participants and is designed as a randomized, double-blind, placebo-controlled, multi-center study [2]. Group 2: Market Context and Potential - There is a substantial patient base for chronic hepatitis B in China, with approximately 93 million infected individuals and 20.23 million patients as of 2023 [2]. - The World Health Organization has set a target to eliminate viral hepatitis as a public health threat by 2030, aiming for a 90% reduction in new infections and a 65% reduction in mortality [2]. Group 3: Company Background and R&D Strength - Weikang Pharmaceutical has established itself as a modern high-tech pharmaceutical company with a diverse production system covering various dosage forms [1][3]. - The company has developed a robust research and development framework, including multiple provincial-level research centers and collaborations with notable scientists, enhancing its competitive edge in the pharmaceutical industry [3]. Group 4: Future Outlook - The successful completion of the Phase III trial for "Huangjia Soft Liver Granules" could lead to new treatment options for liver fibrosis and contribute to improving the management of chronic hepatitis B in China [4]. - Weikang Pharmaceutical aims to leverage technological innovation to strengthen its R&D capabilities and expand its portfolio of quality traditional Chinese medicine products [4].

Core Viewpoint - The announcement indicates that Weikang Pharmaceutical is collaborating with Yingkerui (Zhuhai Jinwan) Pharmaceutical Co., Ltd. to initiate a Phase III clinical trial for Huangjia Soft Liver Granules, aimed at evaluating its efficacy and safety in treating chronic hepatitis B-related liver fibrosis [1] Group 1 - Weikang Pharmaceutical and Yingkerui are jointly applying for a clinical trial [1] - The leading unit for the trial is Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital, with participation from 19 clinical trial centers including Anhui Medical University First Affiliated Hospital and Chongqing University Affiliated Three Gorges Hospital [1] - The trial is designed as a randomized, double-blind, multi-center, placebo-controlled study [1] Group 2 - The company will actively promote the Phase III clinical trial of Huangjia Soft Liver Granules in accordance with national requirements and expert recommendations following the project kickoff meeting [1]